Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company, announced that Noble Capital Markets has initiated company-sponsored equity research coverage. The company is currently conducting the Phase III FLAMINGO-01 clinical trial to evaluate GLSI-100, their immunotherapy treatment designed to prevent breast cancer recurrences.
Greenwich LifeSciences (NASDAQ:GLSI), una società biofarmaceutica in fase clinica, ha annunciato che Noble Capital Markets ha avviato una copertura di ricerca azionaria promossa dall'azienda. Attualmente la società sta conducendo il trial clinico di Fase III FLAMINGO-01 per valutare GLSI-100, la loro immunoterapia pensata per prevenire le recidive del cancro al seno.
Greenwich LifeSciences (NASDAQ:GLSI), una compañía biofarmacéutica en fase clínica, anunció que Noble Capital Markets inició una cobertura de investigación de acciones patrocinada por la compañía. Actualmente la empresa está llevando a cabo el ensayo clínico de Fase III FLAMINGO-01 para evaluar GLSI-100, su inmunoterapia diseñada para prevenir las recurrencias del cáncer de mama.
Greenwich LifeSciences (NASDAQ:GLSI)는 임상 단계 생명공학 회사로서 Noble Capital Markets가 회사 후원 주식 리서치 커버리지를 시작했다고 발표했습니다. 회사는 현재 재발성 유방암을 예방하기 위해 설계된 면역치료제 GLSI-100을 평가하는 3상 임상시험 FLAMINGO-01을 진행 중입니다.
Greenwich LifeSciences (NASDAQ:GLSI), une société biopharmaceutique en phase clinique, a annoncé que Noble Capital Markets a lancé une couverture de recherche sur actions sponsorisée par la société. L'entreprise mène actuellement l'essai clinique de phase III FLAMINGO-01 visant à évaluer GLSI-100, son immunothérapie conçue pour prévenir les récidives du cancer du sein.
Greenwich LifeSciences (NASDAQ:GLSI), ein Biopharmaunternehmen in der klinischen Phase, gab bekannt, dass Noble Capital Markets eine vom Unternehmen gesponserte Aktienforschungsberichterstattung aufgenommen hat. Das Unternehmen führt derzeit die Phase-III-Studie FLAMINGO-01 durch, um GLSI-100 zu evaluieren, ihre Immuntherapie zur Verhinderung von Brustkrebserkrankungsrezidiven.
- None.
- None.
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available here:
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
FAQ
What is Greenwich LifeSciences' (GLSI) main product candidate?
What phase is Greenwich LifeSciences' (GLSI) FLAMINGO-01 trial currently in?
Who initiated research coverage on Greenwich LifeSciences (GLSI) in August 2025?
What type of company is Greenwich LifeSciences (GLSI)?
